Zobrazeno 1 - 10
of 31
pro vyhledávání: '"Douglas, Sborov"'
Autor:
Saurabh Zanwar, Surbhi Sidana, Leyla Shune, Omar Castaneda Puglianini, Oren Pasvolsky, Rebecca Gonzalez, Danai Dima, Aimaz Afrough, Gurbakhash Kaur, James A. Davis, Megan Herr, Hamza Hashmi, Peter Forsberg, Douglas Sborov, Larry D. Anderson Jr, Joseph P. McGuirk, Charlotte Wagner, Alex Lieberman-Cribbin, Adriana Rossi, Ciara L. Freeman, Frederick L. Locke, Shambavi Richard, Jack Khouri, Yi Lin, Krina K. Patel, Shaji K. Kumar, Doris K. Hansen
Publikováno v:
Journal of Hematology & Oncology, Vol 17, Iss 1, Pp 1-11 (2024)
Abstract Idecabtagene vicleucel (Ide-cel) has demonstrated excellent efficacy and durable responses in patients with relapsed/refractory multiple myeloma (RRMM). However, the outcomes with ide-cel in patients with extramedullary disease (EMD) remain
Externí odkaz:
https://doaj.org/article/681de79c8e1349a19906516ee568e2af
Autor:
Ghulam Rehman Mohyuddin, Samuel M. Rubinstein, Shaji Kumar, S. Vincent Rajkumar, Rafael Fonseca, Nadine H. Abdallah, Gregory S. Calip, Xiaoyan Wang, Christina M. Parrinello, Douglas Sborov
Publikováno v:
Blood Cancer Journal, Vol 14, Iss 1, Pp 1-3 (2024)
Externí odkaz:
https://doaj.org/article/43494671ef6e40a28912afcb49e105cb
Autor:
Karun Neupane, Gliceida Galarza Fortuna, Riyasha Dahal, Timothy Schmidt, Rafael Fonseca, Rajshekhar Chakraborty, Kelly Ann Koehn, Meera Mohan, Hira Mian, Luciano J. Costa, Douglas Sborov, Ghulam Rehman Mohyuddin
Publikováno v:
Blood Cancer Journal, Vol 14, Iss 1, Pp 1-8 (2024)
Abstract Extra copies of chromosome 1q21 (+1q: gain = 3 copies, amp >= 4 copies) are associated with worse outcomes in multiple myeloma (MM). This systematic review assesses the current reporting trends of +1q, the efficacy of existing regimens on +1
Externí odkaz:
https://doaj.org/article/b50ed44cce2d4796a922eef0565c1e2e
Autor:
Ghulam Rehman Mohyuddin, Rajshekhar Chakraborty, Gregory S. Calip, Mustafa S. Ascha, Xiaoliang Wang, Samuel M. Rubinstein, Sascha Tuchman, Luciano Costa, Benjamin Haaland, Smith Giri, Hira Mian, Rafael Fonseca, Douglas Sborov
Publikováno v:
Blood Cancer Journal, Vol 12, Iss 12, Pp 1-5 (2022)
Externí odkaz:
https://doaj.org/article/0b473338ad62480b8964176db706dd81
Autor:
Kellen Gil, Saqib Abbasi, Kathan Mehta, Brian McClune, Douglas Sborov, Nausheen Ahmed, Al-Ola Abdallah, Siddhartha Ganguly, Joseph McGuirk, Leyla Shune, Ghulam Rehman Mohyuddin
Publikováno v:
Clinical Hematology International, Vol 4, Iss 1-2, Pp 56-59 (2022)
Externí odkaz:
https://doaj.org/article/f9fd2a5a2a394e85b4b1c6000ab3a13c
Autor:
Evguenia Ouchveridze, Rahul Banerjee, Aakash Desai, Muhammad Aziz, Wade Lee-Smith, Hira Mian, Katherine Berger, Brian McClune, Douglas Sborov, Muzaffar Qazilbash, Shaji Kumar, Ghulam Rehman Mohyuddin
Publikováno v:
Blood Cancer Journal, Vol 12, Iss 4, Pp 1-9 (2022)
Abstract Hematologic malignancy outcomes have remarkably improved in the past decade with further advancement expected in future years. However, the detrimental effects of financial toxicity (FT) on patients with hematologic malignancies, because of
Externí odkaz:
https://doaj.org/article/83d6020ff18240ae9fbce99d4f4d68af
Autor:
Sagar Lonial, Ajay K. Nooka, Praneetha Thulasi, Ashraf Z. Badros, Bennie H. Jeng, Natalie S. Callander, Heather A. Potter, Douglas Sborov, Brian E. Zaugg, Rakesh Popat, Simona Degli Esposti, Julie Byrne, Joanna Opalinska, January Baron, Trisha Piontek, Ira Gupta, Reza Dana, Asim V. Farooq, Kathryn Colby, Andrzej Jakubowiak
Publikováno v:
Blood Cancer Journal, Vol 11, Iss 5, Pp 1-11 (2021)
Abstract Belantamab mafodotin (belamaf) demonstrated deep and durable responses in patients with heavily pretreated relapsed or refractory multiple myeloma (RRMM) in DREAMM-2 (NCT03525678). Corneal events, specifically keratopathy (including superfic
Externí odkaz:
https://doaj.org/article/f4fbded7918448a587750cd9f85b8f33
Autor:
Saqib Abbasi, John Roller, Al-Ola Abdallah, Leyla Shune, Brian McClune, Douglas Sborov, Ghulam Rehman Mohyuddin
Publikováno v:
BMC Cancer, Vol 21, Iss 1, Pp 1-6 (2021)
Abstract Background Despite advances in treatment, multiple myeloma (MM) remains incurable and results in significant morbidity and mortality. Further research investigating where MM patients die and characterization of end-of-life hospitalizations i
Externí odkaz:
https://doaj.org/article/78db0d72e06f4037bf9b6a2474128d1f
Autor:
Asim V. Farooq, Simona Degli Esposti, Rakesh Popat, Praneetha Thulasi, Sagar Lonial, Ajay K. Nooka, Andrzej Jakubowiak, Douglas Sborov, Brian E. Zaugg, Ashraf Z. Badros, Bennie H. Jeng, Natalie S. Callander, Joanna Opalinska, January Baron, Trisha Piontek, Julie Byrne, Ira Gupta, Kathryn Colby
Publikováno v:
Ophthalmology and Therapy, Vol 9, Iss 4, Pp 889-911 (2020)
Abstract Introduction Patients with relapsed or refractory multiple myeloma (RRMM) represent an unmet clinical need. Belantamab mafodotin (belamaf; GSK2857916) is a first-in-class antibody–drug conjugate (ADC; or immunoconjugate) that delivers a cy
Externí odkaz:
https://doaj.org/article/c9f8e5b32350407bb7943466355dff73
Autor:
Asim V. Farooq, Simona Degli Esposti, Rakesh Popat, Praneetha Thulasi, Sagar Lonial, Ajay K. Nooka, Andrzej Jakubowiak, Douglas Sborov, Brian E. Zaugg, Ashraf Z. Badros, Bennie H. Jeng, Natalie S. Callander, Joanna Opalinska, January Baron, Trisha Piontek, Julie Byrne, Ira Gupta, Kathryn Colby
Publikováno v:
Ophthalmology and Therapy, Vol 9, Iss 4, Pp 913-915 (2020)
The authors of the above mentioned article would like to highlight the following corrections, based upon recent changes to the FDA label and guidance on the use of belamaf
Externí odkaz:
https://doaj.org/article/71703d0b771d43d492eca3051569effb